Matches in Wikidata for { <http://www.wikidata.org/entity/Q82766552> ?p ?o ?g. }
Showing items 1 to 53 of
53
with 100 items per page.
- Q82766552 description "article scientifique publié en 2008" @default.
- Q82766552 description "artículu científicu espublizáu en payares de 2008" @default.
- Q82766552 description "im November 2008 veröffentlichter wissenschaftlicher Artikel" @default.
- Q82766552 description "scientific article published on 29 November 2008" @default.
- Q82766552 description "wetenschappelijk artikel" @default.
- Q82766552 description "наукова стаття, опублікована в листопаді 2008" @default.
- Q82766552 name "Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 tria" @default.
- Q82766552 name "Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 tria" @default.
- Q82766552 type Item @default.
- Q82766552 label "Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 tria" @default.
- Q82766552 label "Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 tria" @default.
- Q82766552 prefLabel "Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 tria" @default.
- Q82766552 prefLabel "Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 tria" @default.
- Q82766552 P1433 Q82766552-179189F8-5DB7-4A26-80A1-98CC0A0AC0BE @default.
- Q82766552 P1476 Q82766552-24346767-47EC-43B1-846B-13087151B863 @default.
- Q82766552 P2093 Q82766552-024E6A22-16FF-4F07-894B-78296DC5C4B2 @default.
- Q82766552 P2093 Q82766552-17480E3E-AD33-439A-8041-1CE66E54A1F8 @default.
- Q82766552 P2093 Q82766552-6DBC8FF2-D78E-412F-9C9D-A452D8D48846 @default.
- Q82766552 P2093 Q82766552-796ECBC4-FDB3-4507-814C-5DACBDDA26BF @default.
- Q82766552 P2093 Q82766552-82D49F74-30C6-4617-981E-271EFFD099D5 @default.
- Q82766552 P2093 Q82766552-9AAD803B-11C2-4975-BCF9-D8217D5E4B65 @default.
- Q82766552 P2093 Q82766552-9C49AECE-13D9-461A-88DF-8579012679AE @default.
- Q82766552 P2093 Q82766552-BBE38334-53D2-49B9-B708-40665F8C3AE8 @default.
- Q82766552 P304 Q82766552-C449B555-A7ED-4BCA-A425-5370FF5CFBC1 @default.
- Q82766552 P31 Q82766552-1161E924-950D-46AA-A124-E66F75A37961 @default.
- Q82766552 P356 Q82766552-F0F5F171-928E-4A66-B890-E0EDE7F9E456 @default.
- Q82766552 P433 Q82766552-091496F9-D2B3-4A1C-BA42-7FFA971A69E1 @default.
- Q82766552 P478 Q82766552-1663C686-D5C3-4A9D-81B3-35C2571FBC8B @default.
- Q82766552 P577 Q82766552-FB2B2929-51C4-4409-B587-C2B6FEC8DDD6 @default.
- Q82766552 P698 Q82766552-8B26943D-21FD-4DCF-81C2-6C4917A8990F @default.
- Q82766552 P921 Q82766552-AF871655-5927-4119-9C14-C60C0930565D @default.
- Q82766552 P921 Q82766552-FE0AE0BC-4775-474B-91F4-349949304064 @default.
- Q82766552 P356 J.EURURO.2008.11.002 @default.
- Q82766552 P698 19042080 @default.
- Q82766552 P1433 Q15763991 @default.
- Q82766552 P1476 "Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial" @default.
- Q82766552 P2093 "Armelle Caty" @default.
- Q82766552 P2093 "Bernard A Zonnenberg" @default.
- Q82766552 P2093 "De Phung" @default.
- Q82766552 P2093 "Michael Borre" @default.
- Q82766552 P2093 "Nancy A Dawson" @default.
- Q82766552 P2093 "Nicholas D James" @default.
- Q82766552 P2093 "Philippe Beuzeboc" @default.
- Q82766552 P2093 "Thomas Morris" @default.
- Q82766552 P304 "1112-1123" @default.
- Q82766552 P31 Q13442814 @default.
- Q82766552 P356 "10.1016/J.EURURO.2008.11.002" @default.
- Q82766552 P433 "5" @default.
- Q82766552 P478 "55" @default.
- Q82766552 P577 "2008-11-29T00:00:00Z" @default.
- Q82766552 P698 "19042080" @default.
- Q82766552 P921 Q181257 @default.
- Q82766552 P921 Q269829 @default.